Skip to main content

Table 1 Patient demographics and lung function at screening/baseline (intent-to-treat population)

From: Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial

 

Placebo OD PM (N = 111)

FF 50 mcg OD PM (N = 111)

Age, mean (SD)

33.8 (13.90)

36.7 (16.16)

Age range, years

12–68

12–77

Female, n (%)

70 (63)

63 (57)

Race, n (%)

  American Indian or Alaska Native

59 (53)

45 (41)

  White

29 (26)

42 (38)

  American Indian or Alaska Native and White

21 (19)

24 (22)

  Other

2 (2)

0

Screening characteristics, mean (SD)

Pre-bronchodilator FEV1 (L)

2.527 (0.6940)

2.452 (0.6843)

Percent predicted FEV1, %

77.33 (12.884)

74.71 (9.493)

Post-bronchodilator FEV1 (L)

3.139 (0.8784)

3.047 (0.8443)

Percent reversibility FEV1, %

24.32 (10.368)

24.77 (9.906)

Baseline characteristics, mean (SD)

Pre-bronchodilator FEV1* (L)

2.712 (0.8305)

2.669 (0.8172)

Percent predicted FEV1*, %

82.30 (14.115)

80.85 (12.277)

Rescue-free 24-h periods, %

7.5 (21.04)

10.2 (21.49)

Symptom-free 24-h periods, %

3.2 (12.73)

5.0 (14.53)

PM PEF (L/min)

356.8 (120.53)

359.0 (121.14)

AM PEF (L/min)

350.3 (115.89)

349.2 (117.21)

  1. *Assessed in 110 patients from each treatment arm; FEV1 = forced expiratory volume in one second; FF = fluticasone furoate; OD = once daily; PEF = peak expiratory flow PM = evening; SD = standard deviation.